Table 2.
Tumor characteristics, n = 130
| Tumor location | |
| Right | 52 (40.6%) |
| Left | 74 (57.8%) |
| Both sides | 2 (1.6%) |
| Focality | |
| Unifocal | 124 (95.4%) |
| Bifocal | 4 (3.1%) |
| Multicentric | 2 (1.5%) |
| Histology | |
| No special type (NST) | 101 (77.7%) |
| Lobular | 27 (20.8%) |
| Mucinous | 2 (1.5%) |
| Grading | |
| G1 | 25 (19.2%) |
| G2 | 76 (58.5%) |
| G3 | 29 (22.3%) |
| Estrogen receptor status | |
| Positive | 119 (91.5%) |
| Negative | 11 (8.5%) |
| Progesterone receptor status | |
| Positive | 108 (83.1%) |
| Negative | 22 (16.9%) |
| Her2neu status | |
| Positive | 22 (16.9%) |
| Negative | 108 (83.1%) |
| Tumor location (quadrant) | |
| Upper-outer | 62 (47.7%) |
| Upper-inner | 26 (20.0%) |
| Lower-outer | 23 (17.7%) |
| Lower-inner | 7 (5.4%) |
| Central | 7 (5.4%) |
| Not known | 5 (3.8%) |
| Distance from nipple-areola complex (cm) | 4.11 ± 3.0 |
| Sonographic tumor-to-skin distance (cm) | 0.86 ± 0.44 |
| Sonographic expansion (largest plane, cm) | 1.3 ± 0.78 |
| Clinical tumor size (cT) | |
| cT1a | 1 (0.8%) |
| cT1b | 28 (21.5%) |
| cT1c | 59 (45.4%) |
| cT2 | 38 (29.2%) |
| cT3 | 3 (2.3%) |
| cT4 | 1 (0.8%) |
| Pathological tumor size after neoadjuvant chemotherapy | |
| ypT0 | 16 (12.3%) |
| ypT1a | 4 (3.1%) |
| ypT1b | 1 (0.8%) |
| ypT1c | 6 (4.6%) |
| ypT2 | 5 (3.8%) |
| ypT3 | 0 (0%) |
| ypT4 | 1 (0.8%) |
| Pathological tumor size without neoadjuvant chemotherapy | |
| pT1a | 3 (2.3%) |
| pT1b | 22 (16.9%) |
| pT1c | 39 (30%) |
| pT2 | 30 (23.1%) |
| pT3 | 2 (1.5%) |
| pT4 | 1 (0.8%) |
| Axillary nodal status, clinical (cN) | |
| cN0 | 106 (81.5%) |
| cN+ | 24 (18.5%) |
| Axillary nodal status, pathological (pN) | |
| pN0 | 95 (73.1%) |
| ≥ pN1 | 31 (23.8%) |
| pNx (unknown) | 4 (3.1%) |
| Tumor palpable (by the physician of the breast unit) | |
| Yes | 75 (57.7%) |
| No | 55 (42.3%) |
n (%)
Results are presented as mean value ± standard deviation (SD)